A proprietary transdermal delivery system utilizing sufentanil, a potent opioid, for the treatment of chronic pain.
View complete product pipeline
August 25, 2014DURECT to Present at the Rodman & Renshaw Investment Conference
August 07, 2014DURECT Corporation Announces Second Quarter 2014 Financial Results and Update of Programs
July 30, 2014DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call
June 27, 2014DURECT Secures $20 Million Debt Financing